Dupixent Hits Endpoints In Adolescents, Filing Expected In Q3
Executive Summary
Positive top-line Phase III results have been released on the use of Sanofi/Regeneron's Dupixent in adolescents with moderate-to-severe atopic dermatitis, adding to the evidence supporting its use in adults.
You may also be interested in...
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
The latest drug development news and highlights from our US FDA Performance Tracker.
Dupixent FDA Asthma Review Bolsters Sanofi And Regeneron
Already approved for atopic dermatitis, the partners have got a PDUFA date of Oct. 20 which could expand the label on their interleukin-4 and -13 inhibitor to include asthma.